Led · Seed · Dec 2018

WhizAI is an augmented analytics platform purpose-built for life sciences and healthcare that delivers AI- and natural-language-driven insights to business users. The company’s product provides conversational, automated and dynamically generated actionable insights intended to remove delays of traditional BI dashboards. WhizAI says it aims to democratize business insights and make analytics business-user oriented, conversational, and augmented with AI and natural language technology. In 2022 the company expanded its footprint with new and existing top global pharma clients, formed strategic partnerships, and added to its leadership, sales and marketing, engineering capacity and product capabilities. It received recognition from Gartner (named in five hype cycles) and was named a “trailblazer” by Everest Group in life sciences commercial analytics and AI. WhizAI has raised a total of $21 million since launching in 2017, following a new round that included strategic investments from Shanda Group and AmerisourceBergen’s AB Health Ventures. WhizAI provides an augmented analytics platform purpose-built for life sciences, combining NLP, machine learning, visualization, and data scalability to deliver domain-specific, contextual insights. The AI is pre-trained in life sciences language and analytics so business users get timely, actionable answers without complex tooling or long wait times. The company says customers can reduce total cost of ownership by roughly 50% while modernizing legacy analytics systems through intelligent automation. WhizAI targets users across sales, commercial operations, marketing, R&D, and supply chain to identify opportunities and eliminate operational inefficiencies. The platform is positioned as fast, easy, and scalable and is used by top global pharma companies. WhizAI plans to use the new capital to expand its footprint in the U.S. and Europe and to invest in hiring, sales, and marketing. WhizAI provides a purpose-built cognitive insights platform for the life sciences that lets users ask business questions using voice or text on web and mobile. Its AI is pre-trained on life sciences vernacular and data and combines natural language processing, data modeling, data visualization and anomaly detection into a single platform. Users can ask questions in their own language to get answers to business questions. The company plans to use the new funding to grow its presence by expanding its team across the globe and investing in sales and marketing. WhizAI is led by co-founder and CEO Rohit Vashisht, and as part of the financing Anya Schiess will join the company’s board of directors. To date the company has raised over $6.5M. WhizAI is a pre-trained, enterprise-focused conversational intelligence platform that provides sales and marketing teams with natural-language access to data, insights, and workflows on desktop and mobile. Its proprietary AI platform can be deployed within a client’s firewall, integrated with multiple data sources, and maintained and customized by client IT teams. WhizAI's customers include large manufacturing and life sciences companies and Fortune 500 clients using the platform to increase rep productivity, institutionalize sales best practices, and empower marketing with AI-powered analytics. The company emphasizes improving adoption of existing data and applications via seamless natural-language access. WhizAI says the new investment and its alliance with Trigyn will help further build out the AI platform and accelerate customer acquisition. Financially, WhizAI announced a $1.1M seed round and has raised $1.6M to date.